 |
 Feature:
Novelos - Research Report Calls For Significant Price Rise. |
|
|
 In
a recent research report published by the Cohen Independent Research Group,
the current $3.50 per share price of biotech Novelos Therapeutics (OTCBB:
NVLT) could more than double over the next 12 months. And
that’s at the low end of the report’s target range.
Once investors read the exhaustive
72-page analysis, the potential for the share price to exceed $14—as the
report states-- within the same one-year time period becomes a definite
possibility.
The 12-month forecasts in the report
are painted within three scenarios and result in a hierarchy of share price
targets ranging from $7.20 to $9.50 to $14.20.
The Cohen report delineates all of
the recent news, relevant numbers and statistics, management depth –a team
with over 70 years of US drug development expertise—as well as the significant
product potential for both Novelos anti-cancer compounds NOV-002 and its
therapy for Hepatitis B and C, NOV-205.
The report also compares Novelos
to the progress of several peers in the sector, making the undervalued
case for NVLT’s current share price at current levels extremely compelling.
A link to the report is provided
here: http://www.smallcapdigest.net/news_images/novelos.pdf.
 Serious
investors interested in Novelos as well as the sector in which it finds
itself need to access and read this exhaustive report.
In our opinion, those investors who
want a detailed look at the current state of cancer therapies and especially
smallcap companies with this sphere will undoubtedly find the information
invaluable.
As you’ll recall from our Trading
Alert on August
1st, and our August
8th report on the NOV-002 Phase 2 results for Non Small Cell Lung
Cancer (NSCLC), the potential for NVLT’s compounds should be of great interest
to investors. In our opinion, the profit potential over the next 12 months
is more than significant.
Accumulation in Novelos shares
continues to be warranted for both trading and long-term investment opportunities.
The shares have pulled backed somewhat
from a recent run to $4.50. The shares look somewhat range bound here between
$3 and $4.50. Our chart shows a nice snapback to the blue 3x3 line, which
in our opinion means that sellers could well be drying up. Traders will
want to position themselves here for a trade to the $4 and change area
while long-term holders should use the pullback to initiate or continue
accumulation. Volumes have been more robust of late allowing those who
want exposure to this unique story better access to shares.
The Cohen Report leaves little
doubt in the depth and potential for Novelos. The publication expands
on the SmallCap Digest’s work on the company, which we brought to the readership
in early August at $3.17. Several trading opportunities have appeared since
and we believe that that trend will continue as well as good returns for
long-term investors.
The Cohen Report goes into significant
detail regarding other potential efficacies for NVLT’s compounds including
as treatment for radiation sickness and psoriasis. As well, considerable
ink is spilled discussing the potential for NOV-002 in the cutting-edge
treatment of refractory cancers (chemo-resistant) such as ovarian.
There’s more…much more. Once
investors have read the Cohen report we believe that NVLT’s potential will
be as apparent to serious biotech investors as it has been and is to the
SmallCap readership.
SmallCap Digest looks forward to
following and providing news and opinion on this unique biotech, which
appears poised for significant price appreciation.
 |
Got comments, questions or suggestions?
Send 'em on over: Editor@smallcapdigest.net
If you wish to send a written request
or inquiry, please send it to our physical address:
TGR Group, LLC
4653 Carmel Mtn Rd Suite 308 #402
San Diego, CA 92130 |
Information is power and timely information is profitable. Become informed and profit from SmallCapDigest Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the SmallCapDigest Email Newsletter on a regular basis.
To ensure newsletter delivery, you can add any additional email addresses you may have to the SmallCapDigest Member List. Receiving the SmallCapDigest Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the SmallCapDigest recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery.
Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the SmallCapDigest, simply follow the instructions located at the bottom of every SmallCapDigest Newsletter Edition.
|
